Amgen exits neuroscience R&D as pharma pulls back from field

Share

Amgen is stopping its neuroscience research – with the exception of programs centered on neuro-inflammation – as the company concluded that their efforts were unlikely to yield long-term success. As a result, approximately 180 roles will be affected. Amgen will instead prioritize cardiovascular disease, oncology, and inflammatory diseases.

 

Over the past several years, many industry leaders have exited or pared down their work on neurological diseases, including Pfizer, Bristol-Myers Squibb, GlaxoSmithKline, and AstraZeneca, as successful results have remained elusive.

 

Read the full article at biopharmadive.com…

Share

Leave a Reply

Your email address will not be published. Required fields are marked *

More in News & Trends
Alexion inks deal to acquire Achillion for $930M upfront

Alexion has struck a deal to buy Achillion for $930M. The takeover will give Alexion two clinical-phase medicines in development...

Close